局部进展期直肠癌器官保留的新辅助治疗：综述
Neoadjuvant Therapy for Organ Preservation in Locally Advanced Rectal Cancer: A Review.
作者信息
Qiu Liangting, Li Jianjun
机构信息
Department of Oncology, The People's Hospital of Tongnan District Chongqing City, Chongqing, 402660, People's Republic of China.
Department of Oncology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, People's Republic of China.
出版信息
Ther Clin Risk Manag. 2025 Aug 20;21:1289-1293. doi: 10.2147/TCRM.S518959. eCollection 2025.
Abstract
Preoperative chemoradiotherapy (CRT) and sphincter-preserving total mesorectal excision (TME) effectively control tumor growth in locally advanced rectal cancer (LARC). However, associated complications can impair the quality of life (QoL) of the patients. Neoadjuvant therapies, such as consolidation neoadjuvant therapy and total neoadjuvant therapy (TNT), can improve tumor regression, potentially achieving a complete response and allowing organ preservation. Emerging clinical data suggest that these approaches can promote long-term cancer control in patients with LARC.
摘要
术前放化疗（CRT）和保留括约肌的全直肠系膜切除术（TME）可有效控制局部晚期直肠癌（LARC）的肿瘤生长。然而，相关并发症会损害患者的生活质量（QoL）。新辅助治疗，如巩固新辅助治疗和全新辅助治疗（TNT），可改善肿瘤退缩，有可能实现完全缓解并保留器官。新出现的临床数据表明，这些方法可促进LARC患者的长期癌症控制。
相似文献
1
Neoadjuvant Therapy for Organ Preservation in Locally Advanced Rectal Cancer: A Review.局部进展期直肠癌器官保留的新辅助治疗：综述
Ther Clin Risk Manag. 2025 Aug 20;21:1289-1293. doi: 10.2147/TCRM.S518959. eCollection 2025.
2
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.A022104/NRG-GI010 联盟：杰纳斯直肠癌试验：一项随机 II/III 期试验，旨在测试三联化疗与双联化疗在局部晚期直肠癌患者的临床完全缓解和无病生存方面的疗效。
BMC Cancer. 2024 Jul 26;24(1):901. doi: 10.1186/s12885-024-12529-7.
3
Total neoadjuvant chemoradiotherapy plus anti PD-1 for mid-to-low locally advanced rectal cancer: study protocol of a prospective, single arm, phase II study (STARS - RC06).全新辅助放化疗联合抗PD-1治疗中低位局部晚期直肠癌：一项前瞻性单臂II期研究（STARS-RC06）的研究方案
Front Oncol. 2025 Aug 8;15:1594927. doi: 10.3389/fonc.2025.1594927. eCollection 2025.
4
Influence of neoadjuvant treatment strategy on perioperative outcomes in locally advanced rectal cancer.新辅助治疗策略对局部进展期直肠癌围手术期结局的影响。
Colorectal Dis. 2024 Apr;26(4):684-691. doi: 10.1111/codi.16929. Epub 2024 Feb 29.
5
Comparative analysis of tumor and mesorectum radiomics in predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.肿瘤与直肠系膜的影像组学在预测局部晚期直肠癌新辅助放化疗反应中的对比分析
Diagn Interv Radiol. 2025 Aug 12. doi: 10.4274/dir.2025.253270.
6
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials.放化疗联合诱导或巩固化疗作为局部晚期直肠癌的新辅助全直肠系膜切除术：CAO/ARO/AIO-12 和 OPRA 随机 2 期试验的汇总分析。
Eur J Cancer. 2024 Oct;210:114291. doi: 10.1016/j.ejca.2024.114291. Epub 2024 Aug 22.
7
Treatment of Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant Therapy: A Systematic Review and Network Meta-Analysis.局部晚期直肠癌新辅助放化疗时代的治疗选择：系统评价和网络荟萃分析。
JAMA Netw Open. 2024 Jun 3;7(6):e2414702. doi: 10.1001/jamanetworkopen.2024.14702.
8
Clinicopathological factors predict residual lymph node metastasis in locally advanced rectal cancer with ypT0-2 after neoadjuvant chemoradiotherapy.临床病理因素预测新辅助放化疗后局部晚期直肠癌 ypT0-2 患者的残留淋巴结转移。
J Cancer Res Clin Oncol. 2024 Apr 4;150(4):176. doi: 10.1007/s00432-024-05662-0.
9
Evaluating the Impact of Induction and Consolidation Total Neoadjuvant Therapies Compared to Conventional Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Network Meta-analysis.评估诱导和巩固性全新辅助治疗与传统放化疗相比对局部晚期直肠癌的影响：一项系统评价和网状Meta分析
Dis Colon Rectum. 2025 Jun 1;68(6):687-701. doi: 10.1097/DCR.0000000000003687. Epub 2025 Mar 10.
10
Neoadjuvant Treatment for Locally Advanced Rectal Cancer: Current Status and Future Directions.局部晚期直肠癌的新辅助治疗：现状与未来方向
Cancers (Basel). 2025 Jul 31;17(15):2540. doi: 10.3390/cancers17152540.
本文引用的文献
1
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.《直肠癌（2022 年第 2 版）》，美国国家综合癌症网络（NCCN）肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Oct;20(10):1139-1167. doi: 10.6004/jnccn.2022.0051.
2
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.局部晚期直肠癌患者的 FOLFIRINOX 新辅助化疗和术前放化疗（UNICANCER-PRODIGE 23）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13.
3
Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.根治性手术与短程放疗联合经肛门内镜微创手术保肛治疗早期直肠癌（TREC）：一项随机、开放标签可行性研究。
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):92-105. doi: 10.1016/S2468-1253(20)30333-2. Epub 2020 Dec 11.
4
Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by Status in Patients With Locally Advanced Rectal Cancer.多中心、随机、III 期临床试验：卡培他滨和伊立替康新辅助放化疗，指导局部进展期直肠癌患者的 状态。
J Clin Oncol. 2020 Dec 20;38(36):4231-4239. doi: 10.1200/JCO.20.01932. Epub 2020 Oct 29.
5
Prognostic Significance of Neoadjuvant Rectal Scores in Preoperative Short-Course Radiotherapy and Long-Course Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer.新辅助直肠评分在局部进展期直肠癌术前短程放疗和长程同期放化疗中的预后意义。
Ann Surg Oncol. 2020 Oct;27(11):4309-4318. doi: 10.1245/s10434-020-09018-z. Epub 2020 Aug 13.
6
Neoadjuvant Radiotherapy Dose Escalation in Locally Advanced Rectal Cancer: a Systematic Review and Meta-analysis of Modern Treatment Approaches and Outcomes.局部晚期直肠癌新辅助放疗剂量递增：现代治疗方法和结局的系统评价和荟萃分析。
Clin Oncol (R Coll Radiol). 2021 Jan;33(1):e1-e14. doi: 10.1016/j.clon.2020.06.008. Epub 2020 Jul 12.
7
Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.优化新辅助放化疗后行根治性手术和辅助化疗的局部进展期直肠癌患者奥沙利铂的剂量。
BMC Cancer. 2020 Jun 1;20(1):498. doi: 10.1186/s12885-020-06988-x.
8
Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab.纳武单抗新辅助治疗后局部晚期直肠癌患者的完全缓解
Oncoimmunology. 2019 Sep 19;8(12):e1663108. doi: 10.1080/2162402X.2019.1663108. eCollection 2019.
9
Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?局部进展期直肠癌：术前短程和长程放疗真的等效吗？
Mol Clin Oncol. 2019 May;10(5):555-559. doi: 10.3892/mco.2019.1825. Epub 2019 Mar 14.
10
UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan.直肠肿瘤中 UGT1A1 多态性与伊立替康术前放化疗疗效和毒性的关系。
Cancer Sci. 2018 Dec;109(12):3934-3942. doi: 10.1111/cas.13807. Epub 2018 Oct 22.
Zotero 插件